Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;44(8):1098-1105.
doi: 10.1002/clc.23656. Epub 2021 May 26.

Progressive tricuspid regurgitation and elevated pressure gradient after transvenous permanent pacemaker implantation

Wei-Chieh Lee  1   2 , Hsiu-Yu Fang  2 , Huang-Chung Chen  2 , Yung-Lung Chen  2 , Tzu-Hsien Tsai  2 , Kuo-Li Pan  3 , Yu-Sheng Lin  3 , Wen-Hao Liu  2 , Mien-Cheng Chen  2
Affiliations

Progressive tricuspid regurgitation and elevated pressure gradient after transvenous permanent pacemaker implantation

Wei-Chieh Lee et al. Clin Cardiol. 2021 Aug.

Abstract

Background: The association of postimplant tricuspid regurgitation (TR) and heart failure (HF) hospitalization in patients without HF and preexisting abnormal TR and TR pressure gradient (PG) remain unclear.

Hypothesis: This study aimed to explore the clinical outcomes of progressive postimplant TR after permanent pacemaker (PPM) implantation.

Methods: A total of 1670 patients who underwent a single ventricular or dual-chamber transvenous PPM implantation at our hospital between January 2003 and December 2017 were included in the study. Patients with prior valvular surgery, history of HF, and baseline abnormal TR and TRPG were excluded. Finally, a total of 1075 patients were enrolled in this study. Progressive TR was defined as increased TR grade of ≥2 degrees and TRPG of >30 mmHg after implant.

Results: In 198 (18.4%) patients (group 1) experienced progressive postimplant TR and elevated TRPG, whereas 877 patients (group 2) did not have progressive postimplant TR. Group 1 had larger change in postimplant TRPG (group 1 vs. group 2; 12.8 ± 9.6 mmHg vs. 1.1 ± 7.6 mmHg; p < .001) than group 2. Group 1 had a higher incidence of HF hospitalization compared to group 2 (13.6% vs. 4.7%; p < .001). Preimplant TRPG (HR: 1.075; 95% confidence interval [CI]: 1.032-1.121; p = .001) was an independent predictor of progressive postimplant TR.

Conclusions: After a transvenous ventricular-based PPM implantation, 18.4% of patients experienced progressive postimplant TR and elevated TRPG. Higher preimplant TRPG was an independent predictor of progressive postimplant TR.

Keywords: heart failure hospitalization; transvenous permanent pacemaker implantation; tricuspid regurgitation.

PubMed Disclaimer

Conflict of interest statement

The author declares there is no potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
(A) Changes of the tricuspid regurgitation pressure gradient in group 1. In group 1, the postimplant TRPG was significantly higher than preimplant TRPG (p < .001). (B) The cumulative incident rate of progressive postimplant tricuspid regurgitation. The cumulative rate of progressive postimplant TR increased from 1.3% in the first year to 18.4% in the sixth year. (C) A Kaplan–Meier curve analysis for heart failure hospitalization. Group 1 (with progressive postimplant tricuspid regurgitation and elevated tricuspid regurgitation pressure gradient) had a significantly higher incidence of heart failure hospitalization compared to group 2 (without progressive postimplant tricuspid regurgitation and elevated tricuspid regurgitation pressure gradient) (log‐rank p < .001)
See this image and copyright information in PMC

References

    1. Furman S, Schwedel J. An intracardiac pacemaker for stokes‐Adams seizures. N Engl J Med. 1959;261:943‐948. - PubMed
    1. Akerström F, Pachón M, Puchol A, et al. Chronic right ventricular apical pacing: adverse effects and current therapeutic strategies to minimize them. Int J Cardiol. 2014;173(3):351‐360. - PubMed
    1. Paniagua D, Aldrich HR, Lieberman EH, Lamas GA, Agatston AS. Increased prevalence of significant tricuspid regurgitation in patients with transvenous pacemakers leads. Am J Cardiol. 1998;82(9):1130‐1132. A9. - PubMed
    1. Kim JB, Spevack DM, Tunick PA, et al. The effect of transvenous pacemaker and implantable cardioverter defibrillator lead placement on tricuspid valve function: an observational study. J Am Soc Echocardiogr. 2008;21(3):284‐287. - PubMed
    1. Al‐Bawardy R, Krishnaswamy A, Rajeswaran J, et al. Tricuspid regurgitation and implantable devices. Pacing Clin Electrophysiol. 2015;38(2):259‐266. - PubMed